Santen Pharmaceutical Co., Ltd.

Industry

  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
    • Nutraceuticals
  • Biotechnology
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products
  • Medical Devices
    • Implantable Devices
    • Biomaterials

Other Names/Subsidiaries

  • Chongqing Santen Kerui Pharmaceutical
  • Eyevance Pharmaceuticals
  • Novagali Pharma
  • InnFocus
  • Santen Inc.
See more in Biomedtracker

Latest on Santen Pharmaceutical Co., Ltd.

Scrip

Asia Deal Watch: Apollo Takes A Shine To Chinese Biotech’s Cardiometabolic Candidate

 
• By Joseph Haas, Lisa Takagi, Dexter Jie Yan, and Jung Won Shin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Apollo Licenses Ex-China Rights T

Scrip

Santen Fortifies Glaucoma Strategy With Sepetaprost Japan Filing

 
• By Lisa Takagi

Santen Pharmaceutical Co., Ltd. has filed for global first approval of sepetaprost (study code: STN1012600), its dual agonist of the FP and EP3 receptors, for glaucoma in Japan. The filing, announced

Scrip

Asia Deal Watch: Ocumension Obtains Chinese Rights To Eight Alcon Products

 
• By Joseph Haas, Dexter Jie Yan, Vibha Ravi, and Anju Ghangurde

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. OcuMension Signs Stock-for-Rights

Scrip

Roche’s Vabysmo Sees The Only Growth In RVO

 
• By Elizabeth Cairns

Retinal vein occlusion (RVO) is a minor indication for Roche Holding AG ’s Vabysmo (faricimab), which has just been approved for this use in Europe. But the angiopoietin-2 and VEGF bispecific has one